Profiel
Maureen Deehan is currently the Chief Executive Officer at Vivtex Corp.
She previously worked at Nordic Nanovector ASA as the Head of Corporate Development & Strategy.
She completed her undergraduate degree at the University of Strathclyde and holds a doctorate from the University of Glasgow School of Medicine.
Actieve functies van Maureen Deehan
| Bedrijven | Functie | Begin |
|---|---|---|
| Vivtex Corp. | Algemeen Directeur | 21-02-2023 |
Eerdere bekende functies van Maureen Deehan
| Bedrijven | Functie | Einde |
|---|---|---|
| THOR MEDICAL | Corporate Officer/Principal | - |
Opleiding van Maureen Deehan
| University of Strathclyde | Undergraduate Degree |
| University of Glasgow School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
| Vivtex Corp. |
